Shinji Atagi

3PUBLICATIONS
29CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Aug 23, 2023
A randomized phase III study of docetaxel alone versus docetaxel plus S-1 in patients with previously treated non-small cell lung cancer: JMTO LC09-01.

Shinji Atagi, Takashi Daimon, Kyoichi Okishio

|Jan 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.

Margarita Majem, Jonathan W Goldman, Thomas John

|Sep 15, 2020
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.

Rong Wang, Tadaaki Yamada, Kenji Kita

Pageof 1

Frequent Collaborators

1 joint publications

Rong Wang

1 joint publications

Tadaaki Yamada

1 joint publications

Kenji Kita

1 joint publications

Hirokazu Taniguchi